351 results on '"Mueller, Nicolas J."'
Search Results
2. Intraventricular antibiotics for severe central nervous system infections: a case series
- Author
-
Arheilger, Laura, Barbagallo, Massimo, Rancic, Gaia Sofia, Stretti, Federica, Dietler-Ebner, Sabeth, Mueller, Nicolas J., Keller, Emanuela, Togni, Claudio, and Brandi, Giovanna
- Published
- 2024
- Full Text
- View/download PDF
3. Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study
- Author
-
Kusejko, Katharina, Kouyos, Roger D., Bernasconi, Enos, Boggian, Katia, Braun, Dominique L., Calmy, Alexandra, Cavassini, Matthias, van Delden, Christian, Furrer, Hansjakob, Garzoni, Christian, Hirsch, Hans H., Hirzel, Cedric, Manuel, Oriol, Schmid, Patrick, Khanna, Nina, Haidar, Fadi, Bonani, Marco, Golshayan, Dela, Dickenmann, Michael, Sidler, Daniel, Schnyder, Aurelia, Mueller, Nicolas J., Günthard, Huldrych F., and Schreiber, Peter W.
- Published
- 2024
- Full Text
- View/download PDF
4. Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis
- Author
-
Amico, Patrizia, Aubert, John-David, Banz, Vanessa, Beckmann, Sonia, Beldi, Guido, Berger, Christoph, Berishvili, Ekaterine, Binet, Isabelle, Bochud, Pierre-Yves, Branca, Sanda, Bucher, Heiner, Catana, Emmanuelle, Chalandon, Yves, De Geest, Sabina, De Seigneux Michael Dickenmann, Sophie, Dreifuss, Joëlle Lynn, Duchosal, Michel, Fehr, Thomas, Ferrari-Lacraz, Sylvie, Garzoni, Christian, Gaudet, Christophe, Golshayan, Déla, Goossens, Nicolas, Halter, Jörg, Heim, Dominik, Hess, Christoph, Hillinger, Sven, Hirsch, Hans H., Hirt, Patricia, Hofbauer, Günther, Huynh-Do, Uyen, Immer, Franz, Koller, Michael, Laager, Mirjam, Laesser, Bettina, Lamoth, Frédéric, Lehmann, Roger, Leichtle, Alexander, Manuel, Oriol, Marti, Hans-Peter, Martinelli, Michele, McLin, Valérie, Mellac, Katell, Mercay, Aurelia, Mettler, Karin, Mueller, Nicolas J., Müller, Antonia, Müller-Arndt, Ulrike, Müllhaupt, Beat, Nägeli, Mirjam, Oldani, Graziano, Pascual, Manuel, Passweg, Jakob, Posfay-Barbe, Klara, Rick, Juliane, Rosselet, Anne, Rossi, Simona, Rothlin, Silvia, Ruschitzka, Frank, Schachtner, Thomas, Schanz, Urs, Schaub, Stefan, Schwab, Simon, Schnyder, Aurelia, Schuurmans, Macé, Sengstag, Thierry, Simonetta, Federico, Steiger, Jürg, Stirniman, Guido, Stürzinger, Ueli, Van Delden, Christian, Venetz, Jean-Pierre, Villard, Jean, Vionnet, Julien, Wick, Madeleine, Wilhlem, Markus, Yerly, Patrick, Halfon, Matthieu, Taffé, Patrick, Bucher, Christian, Haidar, Fadi, Huynh-do, Uyen, Mani, Laila-Yasmin, Wehmeier, Caroline, Fakhouri, Fadi, and Golshayan, Dela
- Published
- 2024
- Full Text
- View/download PDF
5. Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges
- Author
-
Giannella, Maddalena, Lanternier, Fanny, Dellière, Sarah, Groll, Andreas H., Mueller, Nicolas J., Alastruey-Izquierdo, Ana, and Slavin, Monica A.
- Published
- 2024
- Full Text
- View/download PDF
6. Epidemiology and outcomes of medically attended and microbiologically confirmed bacterial foodborne infections in solid organ transplant recipients
- Author
-
van den Bogaart, Lorena, Lang, Brian M., Neofytos, Dionysios, Egli, Adrian, Walti, Laura N., Boggian, Katia, Garzoni, Christian, Berger, Christoph, Pascual, Manuel, van Delden, Christian, Mueller, Nicolas J., Manuel, Oriol, and Mombelli, Matteo
- Published
- 2022
- Full Text
- View/download PDF
7. No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts
- Author
-
Wright, Edwina J, Grund, Birgit, Robertson, Kevin R, Cysique, Lucette, Brew, Bruce J, Collins, Gary L, Poehlman-Roediger, Mollie, Vjecha, Michael J, Penalva de Oliveira, Augusto César, Standridge, Barbara, Carey, Cate, Avihingsanon, Anchalee, Florence, Eric, Lundgren, Jens D, Arenas-Pinto, Alejandro, Mueller, Nicolas J, Winston, Alan, Nsubuga, Moses S, Lal, Luxshimi, and Price, Richard W
- Subjects
Infectious Diseases ,HIV/AIDS ,Clinical Research ,Neurosciences ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,AIDS Dementia Complex ,Adult ,Anti-Retroviral Agents ,CD4 Lymphocyte Count ,Female ,HIV Infections ,Humans ,Longitudinal Studies ,Male ,Secondary Prevention ,Treatment Outcome ,antiretroviral treatment ,central nervous system ,HAND ,HIV ,neurocognitive impairment ,INSIGHT START Neurology Substudy Group ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology - Abstract
ObjectiveTo compare the effect of immediate versus deferred antiretroviral treatment (ART) on neuropsychological test performance in treatment-naive HIV-positive adults with more than 500 CD4 cells/μl.DesignRandomized trial.MethodsThe START parent study randomized participants to commence immediate versus deferred ART until CD4 less than 350 cells/μl. The START Neurology substudy used eight neuropsychological tests, at baseline, months 4, 8, 12 and annually, to compare groups for changes in test performance. Test results were internally standardized to z-scores. The primary outcome was the average of the eight test z-scores (QNPZ-8). Mean changes in QNPZ-8 from baseline were compared by intent-to-treat using longitudinal mixed models. Changes from baseline to specific time points were compared using ANCOVA models.ResultsThe 592 participants had a median age of 34 years; median baseline CD4 count was 629 cells/μl; the mean follow-up was 3.4 years. ART was used for 94 and 32% of accrued person-years in the immediate and deferred groups, respectively. There was no difference between the immediate and deferred ART groups in QNPZ-8 change through follow-up [-0.018 (95% CI -0.062 to 0.027, P = 0.44)], or at any visit. However, QNPZ-8 scores increased in both arms during the first year, by 0.22 and 0.24, respectively (P
- Published
- 2018
8. Burden, epidemiology, and outcomes of microbiologically confirmed respiratory viral infections in solid organ transplant recipients: a nationwide, multi-season prospective cohort study
- Author
-
Mombelli, Matteo, Lang, Brian M., Neofytos, Dionysios, Aubert, John-David, Benden, Christian, Berger, Christoph, Boggian, Katia, Egli, Adrian, Soccal, Paola M., Kaiser, Laurent, Hirzel, Cédric, Pascual, Manuel, Koller, Michael, Mueller, Nicolas J., van Delden, Christian, Hirsch, Hans H., and Manuel, Oriol
- Published
- 2021
- Full Text
- View/download PDF
9. Immunogenicity of High-Dose Versus MF59-Adjuvanted Versus Standard Influenza Vaccine in Solid Organ Transplant Recipients: The Swiss/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU Trial)
- Author
-
Swiss National Science Foundation, Sánchez-Céspedes, Javier [0000-0003-2707-1979], Mombelli, Matteo, Neofytos, Dionysios, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M., Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F., Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J., Egli, Adrian, Cordero, Van Delden, Christian, Manuel, Oriol, Swiss National Science Foundation, Sánchez-Céspedes, Javier [0000-0003-2707-1979], Mombelli, Matteo, Neofytos, Dionysios, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M., Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F., Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J., Egli, Adrian, Cordero, Van Delden, Christian, and Manuel, Oriol
- Abstract
[Background] The immunogenicity of the standard influenza vaccine is reduced in solid-organ transplant (SOT) recipients, so new vaccination strategies are needed in this population., [Methods] Adult SOT recipients from 9 transplant clinics in Switzerland and Spain were enrolled if they were >3 months after transplantation. Patients were randomized (1:1:1) to a MF59-adjuvanted or a high-dose vaccine (intervention), or a standard vaccine (control), with stratification by organ and time from transplant. The primary outcome was vaccine response rate, defined as a ≥4-fold increase of hemagglutination-inhibition titers to at least 1 vaccine strain at 28 days postvaccination. Secondary outcomes included polymerase chain reaction–confirmed influenza and vaccine reactogenicity., [Results] A total of 619 patients were randomized, 616 received the assigned vaccines, and 598 had serum available for analysis of the primary endpoint (standard, n = 198; MF59-adjuvanted, n = 205; high-dose, n = 195 patients). Vaccine response rates were 42% (84/198) in the standard vaccine group, 60% (122/205) in the MF59-adjuvanted vaccine group, and 66% (129/195) in the high-dose vaccine group (difference in intervention vaccines vs standard vaccine, 0.20; 97.5% confidence interval [CI], .12–1); P < .001; difference in high-dose vs standard vaccine, 0.24 [95% CI, .16–1]; P < .001; difference in MF59-adjuvanted vs standard vaccine, 0.17 [97.5% CI, .08–1]; P < .001). Influenza occurred in 6% of the standard, 5% in the MF59-adjuvanted, and 7% in the high-dose vaccine groups. Vaccine-related adverse events occurred more frequently in the intervention vaccine groups, but most of the events were mild., [Conclusions] In SOT recipients, use of an MF59-adjuvanted or a high-dose influenza vaccine was safe and resulted in a higher vaccine response rate.
- Published
- 2024
10. Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID‐19 prevention
- Author
-
Trepl, Julia; https://orcid.org/0000-0001-8197-5595, Pasin, Chloé; https://orcid.org/0000-0001-8730-790X, Schneidawind, Dominik; https://orcid.org/0000-0002-2672-431X, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Bankova, Andriyana K; https://orcid.org/0000-0002-5072-9591, Abela, Irene A; https://orcid.org/0000-0002-5566-8628, Trepl, Julia; https://orcid.org/0000-0001-8197-5595, Pasin, Chloé; https://orcid.org/0000-0001-8730-790X, Schneidawind, Dominik; https://orcid.org/0000-0002-2672-431X, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Bankova, Andriyana K; https://orcid.org/0000-0002-5072-9591, and Abela, Irene A; https://orcid.org/0000-0002-5566-8628
- Abstract
Summary: Allogeneic haematopoietic cell transplantation (allo‐HCT) recipients exhibit an increased risk of COVID‐19, particularly in the early post‐transplant phase, due to insufficient vaccine responses. This retrospective study investigated the incidence of SARS‐CoV‐2 infection in allo‐HCT recipients who received tixagevimab/cilgavimab pre‐exposure prophylaxis (T/C PrEP) compared to those who did not. Logistic regression, adjusted for sex, age, SARS‐CoV‐2 vaccination status and immunosuppressive treatment, revealed a significant reduction in the likelihood of SARS‐CoV‐2 infection risk with T/C PrEP (adjusted odds ratio aOR = 0.26 [0.07, 0.91]). These findings suggest the potential efficacy of monoclonal antibody PrEP in protecting this vulnerable patient population from COVID‐19.
- Published
- 2024
11. Do Infectious Diseases After Kidney Retransplantation Differ From Those After First Kidney Transplantation?
- Author
-
Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, van Delden, Christian; https://orcid.org/0000-0002-2901-8285, Hirsch, Hans H; https://orcid.org/0000-0003-0883-0423, Meylan, Pascal, Boggian, Katia, Hirzel, Cédric; https://orcid.org/0000-0002-7870-912X, Garzoni, Christian; https://orcid.org/0000-0002-0832-2376, Sidler, Daniel; https://orcid.org/0000-0002-2435-5936, Schnyder, Aurelia, Schaub, Stefan; https://orcid.org/0000-0002-9170-1341, Golshayan, Déla, Haidar, Fadi, Bonani, Marco, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Schreiber, Peter W; https://orcid.org/0000-0001-8123-2601, Swiss Transplant Cohort Study, et al, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, van Delden, Christian; https://orcid.org/0000-0002-2901-8285, Hirsch, Hans H; https://orcid.org/0000-0003-0883-0423, Meylan, Pascal, Boggian, Katia, Hirzel, Cédric; https://orcid.org/0000-0002-7870-912X, Garzoni, Christian; https://orcid.org/0000-0002-0832-2376, Sidler, Daniel; https://orcid.org/0000-0002-2435-5936, Schnyder, Aurelia, Schaub, Stefan; https://orcid.org/0000-0002-9170-1341, Golshayan, Déla, Haidar, Fadi, Bonani, Marco, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Schreiber, Peter W; https://orcid.org/0000-0001-8123-2601, Swiss Transplant Cohort Study, and et al
- Abstract
Background Infectious diseases (IDs) are highly relevant after solid organ transplantation in terms of morbidity and mortality, being among the most common causes of death. Patients undergoing kidney retransplantation (re-K-Tx) have been already receiving immunosuppressive therapy over a prolonged period, potentially facilitating subsequent infections. Comparing ID events after re-K-Tx and first kidney transplantation (f-K-Tx) can delineate patterns and risks of ID events associated with prolonged immunosuppression. Methods We included adult patients with records on f-K-Tx and re-K-Tx in the Swiss Transplant Cohort Study. We analyzed ID events after f-K-Tx and re-K-Tx within the same patients and compared infection rates, causative pathogens, and infection sites. Recurrent time-to-event analyses were performed for comparison of infection rates. Results A total of 59 patients with a median age of 47 years (range, 18–73) were included. Overall, 312 ID events in 52 patients occurred. In multivariable recurrent event modeling, the rate of ID events was significantly lower after re-K-Tx (hazard ratio, 0.70; P = .02). More bacterial (68.9% vs 60.4%) and fungal (4.0% vs 1.1%) infections were observed after f-K-Tx but fewer viral infections (27.0% vs 38.5%) as compared with re-K-Tx (P = .11). After f-K-Tx, urinary and gastrointestinal tract infections were more frequent; after re-K-Tx, respiratory tract and surgical site infections were more frequent (P < .001). Conclusions ID events were less frequent after re-K-Tx. Affected sites differed significantly after f-K-Tx vs re-K-Tx.
- Published
- 2024
12. Emergence of novel circoviruses in humans and pigs and their possible importance for xenotransplantation and blood transfusions
- Author
-
Opriessnig, Tanja; https://orcid.org/0000-0001-9642-0904, Xiao, Chao‐Ting; https://orcid.org/0000-0001-5299-5650, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Denner, Joachim; https://orcid.org/0000-0003-3244-6085, Opriessnig, Tanja; https://orcid.org/0000-0001-9642-0904, Xiao, Chao‐Ting; https://orcid.org/0000-0001-5299-5650, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, and Denner, Joachim; https://orcid.org/0000-0003-3244-6085
- Abstract
Background: As sequencing is becoming more broadly available, virus discovery continues. Small DNA viruses contribute to up to 60% of the overall virus load in pigs. Porcine circoviruses (PCVs) are small DNA viruses with a single‐stranded circular genome. They are common in pig breeds and have not been properly addressed for their potential risk in xenotransplantation. Whereas PCV1 is non‐pathogenic in pigs, PCV2 has been associated with various disease manifestations. Recently two new circoviruses have been described, PCV3 and PCV4. While PCV4 is currently present mainly in Asia, PCV3 is widely distributed, and has been identified in commercial pigs, wild boars, and pigs generated for xenotransplantation. In one case PCV3 was transmitted by pigs to baboons via heart transplantation. PCV3 pathogenicity in pigs was controversial initially, however, the virus was found to be associated with porcine dermatitis and nephropathy syndrome (PDNS), reproductive failure, and multisystemic inflammation. Inoculation studies with PCV3 infectious clones confirmed that PCV3 is pathogenic. Most importantly, recently discovered human circoviruses (CV) are closely related to PCV3. Methods: Literature was evaluated and summarized. A dendrogram of existing circoviruses in pigs, humans, and other animal species was created and assessed at the species level.ResultsWe found that human circoviruses can be divided into three species, human CV1, CV2, and CV3. Human CV2 and CV3 are closest to PCV3. Conclusions: Circoviruses are ubiquitous. This communication should create awareness of PCV3 and the newly discovered human circoviruses, which may be a problem for blood transfusions and xenotransplantation in immune suppressed individuals.
- Published
- 2024
13. Immune monitoring-guided vs fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients. A Multicenter, Randomized Clinical Trial
- Author
-
Manuel, Oriol; https://orcid.org/0000-0001-7607-0943, Laager, Mirjam, Hirzel, Cédric, Neofytos, Dionysios, Walti, Laura N, Hoenger, Gideon, Binet, Isabelle, Schnyder, Aurelia, Stampf, Susanne, Koller, Michael, Mombelli, Matteo, Kim, Min Jeong, Hoffmann, Matthias, Koenig, Katrin, Hess, Christoph, Burgener, Anne-Valérie, Cippà, Pietro E; https://orcid.org/0000-0002-9507-0057, Hübel, Kerstin, Mueller, Thomas F; https://orcid.org/0000-0003-2236-2312, Sidler, Daniel, Dahdal, Suzan, Suter-Riniker, Franziska, Villard, Jean, Zbinden, Andrea; https://orcid.org/0000-0001-8328-7614, Pantaleo, Giuseppe, Semmo, Nasser, Hadaya, Karine, Enríquez, Natalia, Meylan, Pascal R, Froissart, Marc, et al, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Manuel, Oriol; https://orcid.org/0000-0001-7607-0943, Laager, Mirjam, Hirzel, Cédric, Neofytos, Dionysios, Walti, Laura N, Hoenger, Gideon, Binet, Isabelle, Schnyder, Aurelia, Stampf, Susanne, Koller, Michael, Mombelli, Matteo, Kim, Min Jeong, Hoffmann, Matthias, Koenig, Katrin, Hess, Christoph, Burgener, Anne-Valérie, Cippà, Pietro E; https://orcid.org/0000-0002-9507-0057, Hübel, Kerstin, Mueller, Thomas F; https://orcid.org/0000-0003-2236-2312, Sidler, Daniel, Dahdal, Suzan, Suter-Riniker, Franziska, Villard, Jean, Zbinden, Andrea; https://orcid.org/0000-0001-8328-7614, Pantaleo, Giuseppe, Semmo, Nasser, Hadaya, Karine, Enríquez, Natalia, Meylan, Pascal R, Froissart, Marc, et al, and Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191
- Abstract
BACKGROUND: The use of assays detecting cytomegalovirus (CMV)-specific T-cell-mediated immunity may individualize the duration of antiviral prophylaxis in transplant recipients. METHODS: In this open-label randomized trial, adult kidney and liver transplant recipients from six centers in Switzerland were enrolled if they were CMV-seronegative with seropositive donors or CMV-seropositive receiving anti-thymocyte globulins. Patients were randomized to a duration of antiviral prophylaxis based on immune-monitoring (intervention) or a fixed duration (control). Patients in the control group were planned to receive 180 days (CMV-seronegative) or 90 days (CMV-seropositive) of valganciclovir. Patients were assessed monthly with a CMV-specific interferon gamma release assay (T-Track® CMV); prophylaxis in the intervention group was stopped if the assay was positive. The primary outcomes were the proportion of patients with clinically significant CMV infection and reduction in days of prophylaxis. Between-group differences were adjusted for CMV serostatus. RESULTS: Overall, 193 patients were randomized (92 in the immune-monitoring and 101 in the control group) of which 185 had evaluation of the primary endpoint (87 and 98 patients, respectively). Clinically significant CMV infection occurred in 26/87 (adjusted percentage, 30.9%) in the immune-monitoring group and in 32/98 (adjusted percentage, 31.1%) in the control group (adjusted risk difference -0.1, 95%CI -13.0%, 12.7%; p = 0.064). The duration of antiviral prophylaxis was shorter in the immune-monitoring group (adjusted difference -26.0 days, 95%-CI -41.1 to -10.8 days, p < 0.001). CONCLUSIONS: Immune monitoring resulted in a significant reduction of antiviral prophylaxis, but we were unable to establish noninferiority of this approach on the co-primary endpoint of CMV infection.
- Published
- 2024
14. Epidemiology, outcomes and risk factors for recurrence of Clostridioides difficile infections following allogeneic hematopoietic cell transplantation: a longitudinal retrospective multicenter study
- Author
-
Ragozzino, Silvio; https://orcid.org/0000-0002-8100-2096, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Passweg, Jakob; https://orcid.org/0000-0001-7092-3351, Müller, Antonia, Medinger, Michael; https://orcid.org/0000-0003-0427-7747, Van Delden, Christian, Masouridi-Levrat, Stavroula; https://orcid.org/0000-0001-7502-5454, Chalandon, Yves; https://orcid.org/0000-0001-9341-8104, Tschudin-Sutter, Sarah, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, Swiss Transplant Cohort Study, Ragozzino, Silvio; https://orcid.org/0000-0002-8100-2096, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Passweg, Jakob; https://orcid.org/0000-0001-7092-3351, Müller, Antonia, Medinger, Michael; https://orcid.org/0000-0003-0427-7747, Van Delden, Christian, Masouridi-Levrat, Stavroula; https://orcid.org/0000-0001-7502-5454, Chalandon, Yves; https://orcid.org/0000-0001-9341-8104, Tschudin-Sutter, Sarah, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, and Swiss Transplant Cohort Study
- Published
- 2024
15. Detection of Scedosporium spp.: Colonizer or pathogen? A retrospective analysis of clinical significance and management in a large tertiary centre
- Author
-
Reinhold, Ilana; https://orcid.org/0000-0002-6222-0418, Quiblier, Chantal, Blaser, Frank, Bögeholz, Jan, Imkamp, Frank, Schuurmans, Macé M; https://orcid.org/0000-0001-5404-7566, Soyka, Michael B; https://orcid.org/0000-0003-4179-4989, Zbinden, Reinhard, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Reinhold, Ilana; https://orcid.org/0000-0002-6222-0418, Quiblier, Chantal, Blaser, Frank, Bögeholz, Jan, Imkamp, Frank, Schuurmans, Macé M; https://orcid.org/0000-0001-5404-7566, Soyka, Michael B; https://orcid.org/0000-0003-4179-4989, Zbinden, Reinhard, and Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191
- Abstract
Infections with Scedosporium spp. are emerging in the past two decades and are associated with a high mortality rate. Microbiological detection can be associated with either a colonization or infection. Evolution from colonization into infection is difficult to predict and clinical management upon microbiological detection is complex. Microbiological samples from 2015 to 2021 were retrospectively analyzed in a single tertiary care centre. Classification into colonization or infection was performed upon first microbiological detection. Clinical evolution was observed until July 2023. Further diagnostic procedures after initial detection were analyzed. Among 38 patients with microbiological detection of Scedosporium spp.,10 were diagnosed with an infection at the initial detection and two progressed from colonization to infection during the observation time. The main sites of infections were lung (5/12; 41.6%) followed by ocular sites (4/12; 33.3%). Imaging, bronchoscopy or biopsies upon detection were performed in a minority of patients. Overall mortality rate was similar in both groups initially classified as colonization or infection (30.7% and 33.3% resp. (p=1.0)). In all patients where surgical debridement of site of infection was performed (5/12; 42%); no death was observed. Although death occurred more often in the group without eradication (3/4; 75%) compared with the group with successful eradication (1/8; 12.5%), statistical significance could not be reached (p=0.053). As therapeutic management directly impacts patients' outcome, a multidisciplinary approach upon microbiological detection of Scedosporium spp. should be encouraged. Data from larger cohorts are warranted in order to analyze contributing factors favoring the evolution from colonization into infection.
- Published
- 2024
16. Immunogenicity of High-Dose vs. MF59-adjuvanted vs. Standard Influenza Vaccine in Solid Organ Transplant Recipients: The STOP-FLU trial
- Author
-
Mombelli, Matteo, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M, Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F, Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J, Egli, Adrian; https://orcid.org/0000-0002-3564-8603, Cordero, Elisa, van Delden, Christian, et al, Mombelli, Matteo, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M, Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F, Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J, Egli, Adrian; https://orcid.org/0000-0002-3564-8603, Cordero, Elisa, van Delden, Christian, and et al
- Abstract
BACKGROUND The immunogenicity of the standard influenza vaccine is reduced in solid-organ transplant (SOT) recipients, so that new vaccination strategies are needed in this population. METHODS Adult SOT recipients from nine transplant clinics in Switzerland and Spain were enrolled if they were >3 months after transplantation. High, with stratification by organ and time from transplant. The primary outcome was vaccine response rate, defined as a ≥4-fold increase of hemagglutination-inhibition titers to at least one vaccine strain at 28 days post-vaccination. Secondary outcomes included PCR-confirmed influenza and vaccine reactogenicity. RESULTS 619 patients were randomized, 616 received the assigned vaccines, and 598 had serum available for analysis of the primary endpoint (standard, n=198; MF59-adjuvanted, n=205; high-dose, n=195 patients). Vaccine response rates were 42% (84/198) in the standard vaccine group, 60% (122/205) in the MF59-adjuvanted vaccine group, and 66% (129/195) in the high-dose vaccine group (difference in intervention vaccines vs. standard vaccine, 0.20 [97.5% CI 0.12-1]; p<0.001; difference in high-dose vs. standard vaccine, 0.24 [95% CI 0.16-1]; p<0.001; difference in MF59-adjuvanted vs. standard vaccine, 0.17 [97.5% CI 0.08-1]; p<0.001). Influenza occurred in 6% the standard, 5% in the MF59-adjuvanted, and 7% in the high-dose vaccine groups. Vaccine-related adverse events occurred more frequently in the intervention vaccine groups, but most of the events were mild. CONCLUSIONS In SOT recipients, use of an MF59-adjuvanted or a high-dose influenza vaccine was safe and resulted in a higher vaccine response rate. TRIAL REGISTRATION Clinicaltrials.gov NCT03699839.
- Published
- 2024
17. Long-Term Follow-Up of Antibody Titers Against Measles, Mumps, and Rubella in Recipients of Allogenic Hematopoietic Cell Transplantation
- Author
-
Bögeholz, Jan, Russkamp, Norman F., Wilk, Christian M., Gourri, Elise, Haralambieva, Eugenia, Schanz, Urs, Mueller, Nicolas J., Manz, Markus G., and Müller, Antonia M.S.
- Published
- 2020
- Full Text
- View/download PDF
18. Elimination of Herpes Simplex Virus-2 and Epstein-Barr Virus With Seraph 100 Microbind Affinity Blood Filter and Therapeutic Plasma Exchange: An Explorative Study in a Patient With Acute Liver Failure
- Author
-
Andermatt, Rea, Bloemberg, Guido V., Ganter, Christoph C., Mueller, Nicolas J., Mueller, Antonia M. S., Muellhaupt, Beat, Kielstein, Jan T., and David, Sascha
- Published
- 2022
- Full Text
- View/download PDF
19. Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients
- Author
-
Quteineh, Lina, Wójtowicz, Agnieszka, Bochud, Pierre-Yves, Crettol, Severine, Vandenberghe, Frederik, Venetz, Jean-Pierre, Manuel, Oriol, Golshayan, Dela, Lehmann, Roger, Mueller, Nicolas J., Binet, Isabelle, van Delden, Christian, Steiger, Jürg, Mohacsi, Paul, Dufour, Jean-Francois, Soccal, Paola M., Kutalik, Zoltan, Marques-Vidal, Pedro, Vollenweider, Peter, Recher, Mike, Hess, Christoph, Pascual, Manuel, and Eap, Chin B.
- Published
- 2019
- Full Text
- View/download PDF
20. Adjunctive glucocorticoid therapy for Pneumocystis jirovecii pneumonia in solid organ transplant recipients: A multicenter cohort, 2015-2020
- Author
-
Hosseini-Moghaddam, Seyed M., primary, Kothari, Sagar, additional, Humar, Atul, additional, Albasata, Hanan, additional, Yetmar, Zachary A., additional, Razonable, Raymund R., additional, Neofytos, Dionysios, additional, D’Asaro, Matilde, additional, Boggian, Katia, additional, Hirzel, Cedric, additional, Khanna, Nina, additional, Manuel, Oriol, additional, Mueller, Nicolas J., additional, Imlay, Hannah, additional, Kabbani, Dima, additional, Tyagi, Varalika, additional, Smibert, Olivia C., additional, Nasra, Mohamed, additional, Fontana, Lauren, additional, Obeid, Karam M., additional, Apostolopoulou, Anna, additional, Zhang, Sean X., additional, Permpalung, Nitipong, additional, Alhatimi, Hind, additional, Silverman, Michael S., additional, Guo, Henry, additional, Rogers, Benjamin A., additional, MacKenzie, Erica, additional, Pisano, Jennifer, additional, Gioia, Francesca, additional, Rapi, Lindita, additional, Prasad, G.V. Ramesh, additional, Banegas, Marcela, additional, Alonso, Carolyn D., additional, Doss, Kathleen, additional, Rakita, Robert M., additional, and Fishman, Jay A., additional
- Published
- 2023
- Full Text
- View/download PDF
21. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation
- Author
-
Huang, Alice, Cicin-Sain, Caroline, Pasin, Chloe, Epp, Selina, Audigé, Annette, Müller, Nicolas J., Nilsson, Jakob, Bankova, Andriyana, Wolfensberger, Nathan, Vilinovszki, Oliver, Nair, Gayathri, Hockl, Philipp, Schanz, Urs, Kouyos, Roger D., Hasse, Barbara, Zinkernagel, Annelies S., Trkola, Alexandra, Manz, Markus G., Abela, Irene A., and Müller, Antonia M.S.
- Published
- 2022
- Full Text
- View/download PDF
22. Genetic and clinic predictors of new onset diabetes mellitus after transplantation
- Author
-
Saigi-Morgui, Núria, Quteineh, Lina, Bochud, Pierre-Yves, Crettol, Severine, Kutalik, Zoltán, Mueller, Nicolas J., Binet, Isabelle, Van Delden, Christian, Steiger, Jürg, Mohacsi, Paul, Dufour, Jean-francois, Soccal, Paola M., Pascual, Manuel, Eap, Chin B., and the Swiss Transplant Cohort Study
- Published
- 2019
- Full Text
- View/download PDF
23. ‘Which trial do we need? Culture of preservation fluid in abdominal organ transplant recipients’ Author's reply
- Author
-
Manuel, Oriol, primary, van den Bogaart, Lorena, additional, Mueller, Nicolas J., additional, and Neofytos, Dionysios, additional
- Published
- 2023
- Full Text
- View/download PDF
24. Do Infectious Diseases After Kidney Retransplantation Differ From Those After First Kidney Transplantation?
- Author
-
Kusejko, Katharina, Neofytos, Dionysios, Delden, Christian van, Hirsch, Hans H, Meylan, Pascal, Boggian, Katia, Hirzel, Cedric, Garzoni, Christian, Sidler, Daniel, Schnyder, Aurelia, Schaub, Stefan, Golshayan, Déla, Haidar, Fadi, Bonani, Marco, Kouyos, Roger D, Mueller, Nicolas J, Schreiber, Peter W, and Study, the Swiss Transplant Cohort
- Abstract
Background Infectious diseases (IDs) are highly relevant after solid organ transplantation in terms of morbidity and mortality, being among the most common causes of death. Patients undergoing kidney retransplantation (re-K-Tx) have been already receiving immunosuppressive therapy over a prolonged period, potentially facilitating subsequent infections. Comparing ID events after re-K-Tx and first kidney transplantation (f-K-Tx) can delineate patterns and risks of ID events associated with prolonged immunosuppression. Methods We included adult patients with records on f-K-Tx and re-K-Tx in the Swiss Transplant Cohort Study. We analyzed ID events after f-K-Tx and re-K-Tx within the same patients and compared infection rates, causative pathogens, and infection sites. Recurrent time-to-event analyses were performed for comparison of infection rates. Results A total of 59 patients with a median age of 47 years (range, 18–73) were included. Overall, 312 ID events in 52 patients occurred. In multivariable recurrent event modeling, the rate of ID events was significantly lower after re-K-Tx (hazard ratio, 0.70; P =.02). More bacterial (68.9% vs 60.4%) and fungal (4.0% vs 1.1%) infections were observed after f-K-Tx but fewer viral infections (27.0% vs 38.5%) as compared with re-K-Tx (P =.11). After f-K-Tx, urinary and gastrointestinal tract infections were more frequent; after re-K-Tx, respiratory tract and surgical site infections were more frequent (P <.001). Conclusions ID events were less frequent after re-K-Tx. Affected sites differed significantly after f-K-Tx vs re-K-Tx. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Toxoplasmosis in Transplant Recipients, Europe, 2010-2014
- Author
-
Robert-Gangneux, Florence, Meroni, Valeria, Dupont, Damien, Botterel, Frangoise, Garcia, Jose M. Aguado, Brenier- Pinchart, Marie-Pierre, Accoceberry, Isabelle, Akan, Hamdi, Abbate, Isabella, Boggian, Katia, Bruschi, Fabrizio, Carratala, Jordi, David, Miruna, Drgona, Lubos, Djurkovic-Djakovic, Olgica, Farinas, Maria Carmen, Genco, Francesca, Gkrania-Klotsas, Effrossyni, Groll, Andreas H., Guy, Edward, Hirzel, Cedric, Khanna, Nina, Kurt, Ozgur, Junie, Lia Monica, Lazzarotto, Tiziana, Len, Oscar, Mueller, Nicolas J., Munoz, Patricia, Pana, Zoi Dorothea, Roilides, Emmanuel, Stajner, Tijana, van Delden, Christian, Villena, Isabelle, Pelloux, Herve, and Manuel, Oriol
- Subjects
Toxoplasmosis -- Health aspects ,Hematopoietic stem cell transplantation -- Health aspects ,Stem cells -- Health aspects ,Organ transplantation -- Health aspects ,Liver -- Health aspects ,Health - Abstract
Toxoplasmosis is a zoonosis that infects humans and other warm-blooded animals worldwide; prevalence and clinical severity vary by geographic area (1). After primary infection, the parasite persists lifelong within dormant [...]
- Published
- 2018
- Full Text
- View/download PDF
26. Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiency—a case report and comprehensive review of the literature
- Author
-
Simonis, Alexander, Fux, Michaela, Nair, Gayathri, Mueller, Nicolas J., Haralambieva, Eugenia, Pabst, Thomas, Pachlopnik Schmid, Jana, Schmidt, Adrian, Schanz, Urs, Manz, Markus G, and Müller, Antonia M. S.
- Published
- 2018
- Full Text
- View/download PDF
27. Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)
- Author
-
Griessbach, Alexandra, Chammartin, Frédérique; https://orcid.org/0000-0001-8959-2724, Abela, Irene A, Amico, Patrizia, Stoeckle, Marcel P, Eichenberger, Anna L, Hasse, Barbara, Braun, Dominique L, Schuurmans, Macé M, Müller, Thomas F, Tamm, Michael, Audigé, Annette, Mueller, Nicolas J, Rauch, Andri, Günthard, Huldrych F, Koller, Michael T, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, Epp, Selina, Amstutz, Alain, Schönenberger, Christof M, Taji Heravi, Ala, Papadimitriou-Olivgeris, Matthaios, Casutt, Alessio, Manuel, Oriol; https://orcid.org/0000-0001-7607-0943, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Bucher, Heiner C, Briel, Matthias; https://orcid.org/0000-0002-2070-5230, Speich, Benjamin; https://orcid.org/0000-0002-3301-8085, Swiss HIV Cohort Study and the Swiss Transplant Cohort Study, Griessbach, Alexandra, Chammartin, Frédérique; https://orcid.org/0000-0001-8959-2724, Abela, Irene A, Amico, Patrizia, Stoeckle, Marcel P, Eichenberger, Anna L, Hasse, Barbara, Braun, Dominique L, Schuurmans, Macé M, Müller, Thomas F, Tamm, Michael, Audigé, Annette, Mueller, Nicolas J, Rauch, Andri, Günthard, Huldrych F, Koller, Michael T, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, Epp, Selina, Amstutz, Alain, Schönenberger, Christof M, Taji Heravi, Ala, Papadimitriou-Olivgeris, Matthaios, Casutt, Alessio, Manuel, Oriol; https://orcid.org/0000-0001-7607-0943, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Bucher, Heiner C, Briel, Matthias; https://orcid.org/0000-0002-2070-5230, Speich, Benjamin; https://orcid.org/0000-0002-3301-8085, and Swiss HIV Cohort Study and the Swiss Transplant Cohort Study
- Abstract
BACKGROUND After basic immunization with 2 mRNA SARS-CoV-2 vaccine doses, only a small proportion of patients who are severely immunocompromised generate a sufficient antibody response. Hence, we assessed the additional benefit of a third SARS-CoV-2 vaccine in patients with different levels of immunosuppression. METHODS In this observational extension of the COVERALL trial (Corona Vaccine Trial Platform), we recruited patients from the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study (ie, lung and kidney transplant recipients). We collected blood samples before and 8 weeks after the third SARS-CoV-2 vaccination with either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech). The primary outcome was the proportion of participants showing an antibody response (Elecsys Anti-SARS-CoV-2 S test; threshold ≥100 U/mL) 8 weeks after the third SARS-CoV-2 vaccination. We also compared the proportion of patients who reached the primary outcome from basic immunization (the first and second vaccines) to the third vaccination. RESULTS Nearly all participants (97.2% [95% CI, 95.9%-98.6%], 564/580) had an antibody response. This response was comparable between mRNA-1273 (96.1% [95% CI, 93.7%-98.6%], 245/255) and BNT162b2 (98.2% [95% CI, 96.7%-99.6%], 319/325). Stratification by cohort showed that 99.8% (502/503) of people living with HIV and 80.5% (62/77) of recipients of solid organ transplants achieved the primary endpoint. The proportion of patients with an antibody response in solid organ transplant recipients improved from the second vaccination (22.7%, 15/66) to the third (80.5%, 62/77). CONCLUSIONS People living with HIV had a high antibody response. The third vaccine increased the proportion of solid organ transplant recipients with an antibody response. Clinical Trials Registration. NCT04805125 (ClinicalTrials.gov).
- Published
- 2023
28. Bacteremia During the First Year After Solid Organ Transplantation: An Epidemiological Update
- Author
-
Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Stampf, Susanne, Hoessly, Linard D, D'Asaro, Matilde, Tang, Gael Nguyen, Boggian, Katia, Hirzel, Cedric, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, Manuel, Oriol, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Van Delden, Christian, Swiss Transplant Cohort Study, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Stampf, Susanne, Hoessly, Linard D, D'Asaro, Matilde, Tang, Gael Nguyen, Boggian, Katia, Hirzel, Cedric, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, Manuel, Oriol, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Van Delden, Christian, and Swiss Transplant Cohort Study
- Abstract
BACKGROUND: There are limited contemporary data on the epidemiology and outcomes of bacteremia in solid organ transplant recipients (SOTr). METHODS: Using the Swiss Transplant Cohort Study registry from 2008 to 2019, we performed a retrospective nested multicenter cohort study to describe the epidemiology of bacteremia in SOTr during the first year post-transplant. RESULTS: Of 4383 patients, 415 (9.5%) with 557 cases of bacteremia due to 627 pathogens were identified. One-year incidence was 9.5%, 12.8%, 11.4%, 9.8%, 8.3%, and 5.9% for all, heart, liver, lung, kidney, and kidney-pancreas SOTr, respectively (P = .003). Incidence decreased during the study period (hazard ratio, 0.66; P < .001). One-year incidence due to gram-negative bacilli (GNB), gram-positive cocci (GPC), and gram-positive bacilli (GPB) was 5.62%, 2.81%, and 0.23%, respectively. Seven (of 28, 25%) Staphylococcus aureus isolates were methicillin-resistant, 2/67 (3%) enterococci were vancomycin-resistant, and 32/250 (12.8%) GNB produced extended-spectrum beta-lactamases. Risk factors for bacteremia within 1 year post-transplant included age, diabetes, cardiopulmonary diseases, surgical/medical post-transplant complications, rejection, and fungal infections. Predictors for bacteremia during the first 30 days post-transplant included surgical post-transplant complications, rejection, deceased donor, and liver and lung transplantation. Transplantation in 2014-2019, CMV donor-negative/recipient-negative serology, and cotrimoxazole Pneumocystis prophylaxis were protective against bacteremia. Thirty-day mortality in SOTr with bacteremia was 3% and did not differ by SOT type. CONCLUSIONS: Almost 1/10 SOTr may develop bacteremia during the first year post-transplant associated with low mortality. Lower bacteremia rates have been observed since 2014 and in patients receiving cotrimoxazole prophylaxis. Variabilities in incidence, timing, and pathogen of bacteremia across different SOT types may be used to tailo
- Published
- 2023
29. Vaccine-Preventable Infections Among Solid Organ Transplant Recipients in Switzerland
- Author
-
Walti, Laura N, Mugglin, Catrina, Mombelli, Matteo, Manuel, Oriol, Hirsch, Hans H, Khanna, Nina, Mueller, Nicolas J, Berger, Christoph, Boggian, Katia, Garzoni, Christian, Neofytos, Dionysios, van Delden, Christian, Mäusezahl, Mirjam, Hirzel, Cédric, Swiss Transplant Cohort Study, Walti, Laura N, Mugglin, Catrina, Mombelli, Matteo, Manuel, Oriol, Hirsch, Hans H, Khanna, Nina, Mueller, Nicolas J, Berger, Christoph, Boggian, Katia, Garzoni, Christian, Neofytos, Dionysios, van Delden, Christian, Mäusezahl, Mirjam, Hirzel, Cédric, and Swiss Transplant Cohort Study
- Abstract
IMPORTANCE Vaccine responses are decreased in solid organ transplant (SOT) recipients, and given the complexity of implementation, vaccination programs may be suboptimal. The actual burden of vaccine-preventable infections (VPIs) among SOT recipients remains unclear. OBJECTIVES To assess the incidence rate of VPIs among SOT recipients and to evaluate whether SOT recipients are at increased risk for specific VPIs compared with the general population. DESIGN, SETTING, AND PARTICIPANTS This nationwide cohort study used data from the Swiss Transplant Cohort Study on VPIs in individuals who underwent SOT from May 2008 to June 2019 (follow-up until December 2019) and data from the Swiss Federal Office of Public Health on notifiable VPIs in the general population in the same period. Data were analyzed from January 2021 to June 2022. EXPOSURES Solid organ transplant. MAIN OUTCOMES AND MEASURES The main outcomes were the incidence rate of the following VPIs in SOT recipients: hepatitis A and B, diphtheria, Haemophilus influenzae infection, influenza, measles, mumps, pertussis, pneumococcal disease, poliomyelitis, meningococcal disease, rubella, tetanus, tick-borne encephalitis, and varicella zoster virus infection. Age-adjusted standardized incidence ratios were used to assess whether VPIs occurred more frequently in SOT recipients compared with the general population. For SOT recipients, factors associated with occurrence of VPIs were explored and the associated morbidity and mortality assessed. RESULTS Of 4967 SOT recipients enrolled (median age, 54 years [IQR, 42-62 years]; 3191 [64.2%] male), 593 (11.9%) experienced at least 1 VPI. The overall VPI incidence rate was higher in the population that underwent SOT (30.57 per 1000 person-years [PY]; 95% CI, 28.24-33.10 per 1000 PY) compared with the general population (0.71 per 1000 PY). The standardized age-adjusted incidence ratio for notifiable VPIs in SOT recipients was higher compared with the general population (27.84; 9
- Published
- 2023
30. Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
- Author
-
Griessbach, Alexandra; https://orcid.org/0000-0003-3726-1856, Chammartin, Frédérique, Abela, Irene A, Amico, Patrizia, Stoeckle, Marcel P, Eichenberger, Anna L, Hasse, Barbara; https://orcid.org/0000-0001-7196-3734, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Schuurmans, Macé Matthew; https://orcid.org/0000-0001-5404-7566, Müller, Thomas F; https://orcid.org/0000-0003-2236-2312, Tamm, Michael, Audigé, Annette, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Koller, Michael T, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, Epp, Selina, Amstutz, Alain; https://orcid.org/0000-0003-1716-993X, Schönenberger, Christof M, Taji Heravi, Ala; https://orcid.org/0000-0003-3752-1611, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Bucher, Heiner C; https://orcid.org/0000-0002-0131-7873, Briel, Matthias; https://orcid.org/0000-0002-2070-5230, Speich, Benjamin; https://orcid.org/0000-0002-3301-8085, Swiss HIV Cohort Study and the Swiss Transplant Cohort Study, Griessbach, Alexandra; https://orcid.org/0000-0003-3726-1856, Chammartin, Frédérique, Abela, Irene A, Amico, Patrizia, Stoeckle, Marcel P, Eichenberger, Anna L, Hasse, Barbara; https://orcid.org/0000-0001-7196-3734, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Schuurmans, Macé Matthew; https://orcid.org/0000-0001-5404-7566, Müller, Thomas F; https://orcid.org/0000-0003-2236-2312, Tamm, Michael, Audigé, Annette, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Koller, Michael T, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, Epp, Selina, Amstutz, Alain; https://orcid.org/0000-0003-1716-993X, Schönenberger, Christof M, Taji Heravi, Ala; https://orcid.org/0000-0003-3752-1611, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Bucher, Heiner C; https://orcid.org/0000-0002-0131-7873, Briel, Matthias; https://orcid.org/0000-0002-2070-5230, Speich, Benjamin; https://orcid.org/0000-0002-3301-8085, and Swiss HIV Cohort Study and the Swiss Transplant Cohort Study
- Abstract
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%-100.0%]) in individuals with different levels of immunosuppression (difference, -2.8% [95% CI, -6.8% to 1.3%]).
- Published
- 2023
31. Donor-derived fulminant herpes simplex virus hepatitis after liver transplantation: Two cases and review of literature
- Author
-
Reinhold, Ilana; https://orcid.org/0000-0002-6222-0418, Teasca, Laurent, Rodriguez, Elena Requejo, Berney, Thierry; https://orcid.org/0000-0002-4230-9378, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Hilty, Matthias; https://orcid.org/0000-0002-2765-881X, Andermatt, Rea; https://orcid.org/0000-0001-8694-1271, Saro, Francesca, Dutkowski, Philipp, Müllhaupt, Beat; https://orcid.org/0000-0002-9020-8192, van Delden, Christian; https://orcid.org/0000-0002-2901-8285, Swiss Transplant Cohort Study (STCS), Reinhold, Ilana; https://orcid.org/0000-0002-6222-0418, Teasca, Laurent, Rodriguez, Elena Requejo, Berney, Thierry; https://orcid.org/0000-0002-4230-9378, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Hilty, Matthias; https://orcid.org/0000-0002-2765-881X, Andermatt, Rea; https://orcid.org/0000-0001-8694-1271, Saro, Francesca, Dutkowski, Philipp, Müllhaupt, Beat; https://orcid.org/0000-0002-9020-8192, van Delden, Christian; https://orcid.org/0000-0002-2901-8285, and Swiss Transplant Cohort Study (STCS)
- Abstract
BACKGROUND Fulminant herpetic hepatitis due to herpes simplex virus (HSV), serotype 1 or 2, is a rare but often fatal complication after solid organ transplantation (SOT). HSV hepatitis in SOT recipients can occur either due to primary infection acquired post transplantation, viral reactivation in a seropositive patient, or as donor-derived infection. Cases of fatal hepatitis have been reported in the liver as well as in other SOT recipients. The fatal outcome is mostly due to delayed diagnosis and treatment, which is explained by the lack of clinical specificity of HSV hepatitis. METHODS We report two cases of fatal donor-derived HSV hepatitis in liver-transplanted recipients. We reviewed all published cases of donor-derived HSV infections after SOT with an evaluation of the presence of prophylaxis and outcome. RESULTS In both liver recipients, the retrospective determination of HSV serostatus was negative, and both cases occurred in the absence of cytomegalovirus or HSV prophylaxis. A review of the literature showed a significant series of cases of severe hepatitis, mostly fatal, as well as the absence of specific preventive therapy guidelines in cases of HSV serology mismatch. CONCLUSIONS The occurrence of two fatal donor-derived hepatitis made the Swiss Transplant Infectious Diseases working group modify its national recommendations regarding pretransplant serostatus determination and HSV prophylaxis after liver transplantation. Further studies are needed to assess this approach.
- Published
- 2023
32. Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation
- Author
-
Bankova, Andriyana K; https://orcid.org/0000-0002-5072-9591, Pasin, Chloé; https://orcid.org/0000-0001-8730-790X, Huang, Alice, Cicin-Sain, Caroline, Epp, Selina, Audigé, Annette, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Nilsson, Jakob; https://orcid.org/0000-0001-5091-8133, Vilinovszki, Oliver; https://orcid.org/0000-0003-0866-1367, Nair, Gayathri, Wolfensberger, Nathan, Hockl, Philipp, Schanz, Urs, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, Kouyos, Roger; https://orcid.org/0000-0002-9220-8348, Hasse, Barbara; https://orcid.org/0000-0001-7196-3734, Zinkernagel, Annelies S; https://orcid.org/0000-0003-4700-1118, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Abela, Irene A; https://orcid.org/0000-0002-5566-8628, Müller, Antonia M S; https://orcid.org/0000-0003-4420-9466, Bankova, Andriyana K; https://orcid.org/0000-0002-5072-9591, Pasin, Chloé; https://orcid.org/0000-0001-8730-790X, Huang, Alice, Cicin-Sain, Caroline, Epp, Selina, Audigé, Annette, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Nilsson, Jakob; https://orcid.org/0000-0001-5091-8133, Vilinovszki, Oliver; https://orcid.org/0000-0003-0866-1367, Nair, Gayathri, Wolfensberger, Nathan, Hockl, Philipp, Schanz, Urs, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, Kouyos, Roger; https://orcid.org/0000-0002-9220-8348, Hasse, Barbara; https://orcid.org/0000-0001-7196-3734, Zinkernagel, Annelies S; https://orcid.org/0000-0003-4700-1118, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Abela, Irene A; https://orcid.org/0000-0002-5566-8628, and Müller, Antonia M S; https://orcid.org/0000-0003-4420-9466
- Abstract
Allogeneic haematopoietic cell transplantation (allo-HCT) recipients show impaired antibody (Ab) response to a standard two-dose vaccination against severe acute respiratory syndrome coronavirus-2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo-HCT recipients we show sufficient neutralisation activity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo-HCT recipients is critical to optimise current vaccination strategies. Keywords
- Published
- 2023
33. Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates
- Author
-
Sava, Mihaela; https://orcid.org/0000-0001-5763-9073, Bättig, Veronika; https://orcid.org/0000-0002-7418-977X, Gerull, Sabine; https://orcid.org/0000-0002-6612-4220, Passweg, Jakob R; https://orcid.org/0000-0001-7092-3351, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, Garzoni, Christian; https://orcid.org/0000-0002-0832-2376, Gerber, Bernhard; https://orcid.org/0000-0003-1708-8558, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Schanz, Urs, Berger, Christoph; https://orcid.org/0000-0002-1730-8824, Chalandon, Yves; https://orcid.org/0000-0001-9341-8104, van Delden, Christian; https://orcid.org/0000-0002-2901-8285, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Stampf, Susanne; https://orcid.org/0000-0003-3399-5078, Franzeck, Fabian C; https://orcid.org/0000-0001-7510-0231, Weisser, Maja; https://orcid.org/0000-0002-0134-1929, Sava, Mihaela; https://orcid.org/0000-0001-5763-9073, Bättig, Veronika; https://orcid.org/0000-0002-7418-977X, Gerull, Sabine; https://orcid.org/0000-0002-6612-4220, Passweg, Jakob R; https://orcid.org/0000-0001-7092-3351, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, Garzoni, Christian; https://orcid.org/0000-0002-0832-2376, Gerber, Bernhard; https://orcid.org/0000-0003-1708-8558, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Schanz, Urs, Berger, Christoph; https://orcid.org/0000-0002-1730-8824, Chalandon, Yves; https://orcid.org/0000-0001-9341-8104, van Delden, Christian; https://orcid.org/0000-0002-2901-8285, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Stampf, Susanne; https://orcid.org/0000-0003-3399-5078, Franzeck, Fabian C; https://orcid.org/0000-0001-7510-0231, and Weisser, Maja; https://orcid.org/0000-0002-0134-1929
- Published
- 2023
34. Bacteremia During the First Year After Solid Organ Transplantation: An Epidemiological Update
- Author
-
Neofytos, Dionysios, Stampf, Susanne, Hoessly, Linard D, D'Asaro, Matilde, Tang, Gael Nguyen, Boggian, Katia, Hirzel, Cedric, Khanna, Nina, Manuel, Oriol, Mueller, Nicolas J, and Van Delden, Christian
- Subjects
610 Medicine & health - Abstract
BACKGROUND There are limited contemporary data on the epidemiology and outcomes of bacteremia in solid organ transplant recipients (SOTr). METHODS Using the Swiss Transplant Cohort Study registry from 2008 to 2019, we performed a retrospective nested multicenter cohort study to describe the epidemiology of bacteremia in SOTr during the first year post-transplant. RESULTS Of 4383 patients, 415 (9.5%) with 557 cases of bacteremia due to 627 pathogens were identified. One-year incidence was 9.5%, 12.8%, 11.4%, 9.8%, 8.3%, and 5.9% for all, heart, liver, lung, kidney, and kidney-pancreas SOTr, respectively (P = .003). Incidence decreased during the study period (hazard ratio, 0.66; P < .001). One-year incidence due to gram-negative bacilli (GNB), gram-positive cocci (GPC), and gram-positive bacilli (GPB) was 5.62%, 2.81%, and 0.23%, respectively. Seven (of 28, 25%) Staphylococcus aureus isolates were methicillin-resistant, 2/67 (3%) enterococci were vancomycin-resistant, and 32/250 (12.8%) GNB produced extended-spectrum beta-lactamases. Risk factors for bacteremia within 1 year post-transplant included age, diabetes, cardiopulmonary diseases, surgical/medical post-transplant complications, rejection, and fungal infections. Predictors for bacteremia during the first 30 days post-transplant included surgical post-transplant complications, rejection, deceased donor, and liver and lung transplantation. Transplantation in 2014-2019, CMV donor-negative/recipient-negative serology, and cotrimoxazole Pneumocystis prophylaxis were protective against bacteremia. Thirty-day mortality in SOTr with bacteremia was 3% and did not differ by SOT type. CONCLUSIONS Almost 1/10 SOTr may develop bacteremia during the first year post-transplant associated with low mortality. Lower bacteremia rates have been observed since 2014 and in patients receiving cotrimoxazole prophylaxis. Variabilities in incidence, timing, and pathogen of bacteremia across different SOT types may be used to tailor prophylactic and clinical approaches.
- Published
- 2023
- Full Text
- View/download PDF
35. Preventing transfer of infectious agents
- Author
-
Denner, Joachim and Mueller, Nicolas J.
- Published
- 2015
- Full Text
- View/download PDF
36. Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates
- Author
-
Sava, Mihaela, Bättig, Veronika, Gerull, Sabine, Passweg, Jakob R, Khanna, Nina, Garzoni, Christian, Gerber, Bernhard, Mueller, Nicolas J, Schanz, Urs, Berger, Christoph, Chalandon, Yves, van Delden, Christian, Neofytos, Dionysios, Stampf, Susanne, Franzeck, Fabian C, Weisser, Maja, University of Zurich, and Weisser, Maja
- Subjects
10234 Clinic for Infectious Diseases ,Transplantation ,10036 Medical Clinic ,2747 Transplantation ,10032 Clinic for Oncology and Hematology ,2720 Hematology ,610 Medicine & health ,Hematology - Published
- 2023
- Full Text
- View/download PDF
37. Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
- Author
-
Griessbach, Alexandra, Chammartin, Frédérique, Abela, Irene A, Amico, Patrizia, Stoeckle, Marcel P, Eichenberger, Anna L, Hasse, Barbara, Braun, Dominique L, Schuurmans, Macé M, Müller, Thomas F, Tamm, Michael, Audigé, Annette, Mueller, Nicolas J, Rauch, Andri, Günthard, Huldrych F, Koller, Michael T, Trkola, Alexandra, Epp, Selina, Amstutz, Alain, Schönenberger, Christof M, Taji Heravi, Ala, Kusejko, Katharina, Bucher, Heiner C, Briel, Matthias, and Speich, Benjamin
- Subjects
610 Medicine & health - Abstract
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%-100.0%]) in individuals with different levels of immunosuppression (difference, -2.8% [95% CI, -6.8% to 1.3%]).
- Published
- 2023
- Full Text
- View/download PDF
38. Porcine cytomegalovirus: A very unwelcome stowaway
- Author
-
Mueller, Nicolas J, University of Zurich, and Mueller, Nicolas J
- Subjects
10234 Clinic for Infectious Diseases ,2403 Immunology ,Transplantation ,Swine ,2747 Transplantation ,Transplantation, Heterologous ,Immunology ,Animals ,Cytomegalovirus ,610 Medicine & health - Published
- 2022
- Full Text
- View/download PDF
39. Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation
- Author
-
Bankova, Andriyana K, Pasin, Chloé, Huang, Alice, Cicin-Sain, Caroline, Epp, Selina, Audigé, Annette, Mueller, Nicolas J, Nilsson, Jakob, Vilinovszki, Oliver, Nair, Gayathri, Wolfensberger, Nathan, Hockl, Philipp, Schanz, Urs, Trkola, Alexandra, Kouyos, Roger, Hasse, Barbara, Zinkernagel, Annelies S, Manz, Markus G, Abela, Irene A, Müller, Antonia M S, University of Zurich, and Müller, Antonia M S
- Subjects
10028 Institute of Medical Virology ,10234 Clinic for Infectious Diseases ,severe acute respiratory syndrome coronavirus ,allogeneic haematopoietic cell transplantation ,vaccine response ,CoV ,2) ,10032 Clinic for Oncology and Hematology ,2720 Hematology ,10033 Clinic for Immunology ,610 Medicine & health ,Hematology ,2 (SARS - Abstract
Allogeneic haematopoietic cell transplantation (allo-HCT) recipients show impaired antibody (Ab) response to a standard two-dose vaccination against severe acute respiratory syndrome coronavirus-2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo-HCT recipients we show sufficient neutralisation activity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo-HCT recipients is critical to optimise current vaccination strategies.
- Published
- 2022
40. Epidemiology and outcomes of bone and joint infections in solid organ transplant recipients
- Author
-
Pham, Truong-Thanh, primary, Andrey, Diego O., additional, Stampf, Susanne, additional, Burkhard, Sara H., additional, Hirzel, Cédric, additional, Tschopp, Johnathan, additional, Ullrich, Kathrin, additional, Strahm, Carol, additional, Schreiber, Peter W., additional, Boillat-Blanco, Noémie, additional, Garzoni, Christian, additional, Khanna, Nina, additional, Manuel, Oriol, additional, Mueller, Nicolas J., additional, Suva, Domizio, additional, van Delden, Christian, additional, Uçkay, Ilker, additional, and Neofytos, Dionysios, additional
- Published
- 2022
- Full Text
- View/download PDF
41. Improving infection reporting in hematology treatment trials
- Author
-
Teh, Benjamin W., Reynolds, Gemma K., Mikulska, Malgorzata, Mueller, Nicolas J., and Slavin, Monica A.
- Published
- 2024
- Full Text
- View/download PDF
42. Infection Risk in the First Year After ABO-incompatible Kidney Transplantation: A Nationwide Prospective Cohort Study
- Author
-
Hirzel, Cédric, Projer, Lea, Atkinson, Andrew, Surial, Bernard, Mueller, Nicolas J, Manuel, Oriol, Mombelli, Matteo, van Delden, Christian, Hirsch, Hans H, Boggian, Katia, Walti, Laura N, Sidler, Daniel, Hadaya, Karine, Dickenmann, Michael, Müller, Thomas F, Binet, Isabelle, Golshayan, Déla, Huynh-Do, Uyen, University of Zurich, and Hirzel, Cédric
- Subjects
Graft Rejection ,Transplantation ,2747 Transplantation ,Graft Survival ,610 Medicine & health ,Infections ,Kidney Transplantation ,ABO Blood-Group System ,Cohort Studies ,10234 Clinic for Infectious Diseases ,Blood Group Incompatibility ,Living Donors ,Humans ,Anemia, Hemolytic, Autoimmune ,Prospective Studies - Abstract
BACKGROUND ABO-incompatible (ABOi) kidney transplantation (KT) expands the kidney donor pool and may help to overcome organ shortage. Nonetheless, concerns about infectious complications associated with ABOi-KT have been raised. METHODS In a nationwide cohort (Swiss Transplant Cohort Study), we compared the risk for infectious complications among ABOi and ABO-compatible (ABOc) renal transplant recipients. Infections needed to fulfill rigorous, prespecified criteria to be classified as clinically relevant. Unadjusted and adjusted competing risk regression models were used to compare the time to the first clinically relevant infection among ABOi-KT and ABOc-KT recipients. Inverse probability weighted generalized mixed-effects Poisson regression was used to estimate incidence rate ratios for infection. RESULTS We included 757 living-donor KT recipients (639 ABOc; 118 ABOi) and identified 717 infection episodes. The spectrum of causative pathogens and the anatomical sites affected by infections were similar between ABOi-KT and ABOc-KT recipients. There was no significant difference in time to first posttransplant infection between ABOi-KT and ABOc-KT recipients (subhazard ratio, 1.24; 95% confidence interval [CI], 0.93-1.66; P = 0.142). At 1 y, the crude infection rate was 1.11 (95% CI, 0.93-1.33) episodes per patient-year for ABOi patients and 0.94 (95% CI, 0.86-1.01) for ABOc-KT recipients. Inverse probability weighted infection rates were similar between groups (adjusted incidence rate ratio, 1.12; 95% CI, 0.83-1.52; P = 0.461). CONCLUSIONS The burden of infections during the first year posttransplant was high but not relevantly different in ABOi-KT and ABOc-KT recipients. Our results highlight that concerns regarding infectious complications should not affect the implementation of ABOi-KT programs.
- Published
- 2022
- Full Text
- View/download PDF
43. Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial
- Author
-
Speich, Benjamin, Chammartin, Frédérique, Abela, Irene A, Amico, Patrizia, Stoeckle, Marcel P, Eichenberger, Anna L, Hasse, Barbara, Braun, Dominique L, Schuurmans, Macé M, Müller, Thomas F, Tamm, Michael, Audigé, Annette, Mueller, Nicolas J, Rauch, Andri, Günthard, Huldrych F, Koller, Michael T, Trkola, Alexandra, Briel, Matthias, Kusejko, Katharina, Bucher, Heiner C, et al, Schanz, Urs, and University of Zurich
- Subjects
10028 Institute of Medical Virology ,10234 Clinic for Infectious Diseases ,10036 Medical Clinic ,10032 Clinic for Oncology and Hematology ,10209 Clinic for Cardiology ,610 Medicine & health ,10035 Clinic for Nephrology ,10178 Clinic for Pneumology - Published
- 2022
- Full Text
- View/download PDF
44. Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV
- Author
-
Chammartin, Frédérique, primary, Kusejko, Katharina, additional, Pasin, Chloé, additional, Trkola, Alexandra, additional, Briel, Matthias, additional, Amico, Patrizia, additional, Stoekle, Marcel P., additional, Eichenberger, Anna L., additional, Hasse, Barbara, additional, Braun, Dominique L., additional, Schuurmans, Macé M., additional, Müller, Thomas F., additional, Tamm, Michael, additional, Mueller, Nicolas J., additional, Rauch, Andri, additional, Koller, Michael T., additional, Günthard, Huldrych F., additional, Bucher, Heiner C., additional, Speich, Benjamin, additional, and Abela, Irene A., additional
- Published
- 2022
- Full Text
- View/download PDF
45. Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort
- Author
-
Koller, Michael T., van Delden, Christian, Müller, Nicolas J., Baumann, Philippe, Lovis, Christian, Marti, Hans-Peter, Fehr, Thomas, Binet, Isabelle, De Geest, Sabina, Bucher, Heiner C., Meylan, Pascal, Pascual, Manuel, and Steiger, Jürg
- Published
- 2013
- Full Text
- View/download PDF
46. Porcine cytomegalovirus: A very unwelcome stowaway
- Author
-
Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191 and Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191
- Published
- 2022
47. Central nervous system infections in solid organ transplant recipients: Results from the Swiss Transplant Cohort Study
- Author
-
van den Bogaart, Lorena, Lang, Brian M, Rossi, Simona, Neofytos, Dionysios, Walti, Laura N, Khanna, Nina, Mueller, Nicolas J, Boggian, Katia, Garzoni, Christian, Mombelli, Matteo, Manuel, Oriol, van den Bogaart, Lorena, Lang, Brian M, Rossi, Simona, Neofytos, Dionysios, Walti, Laura N, Khanna, Nina, Mueller, Nicolas J, Boggian, Katia, Garzoni, Christian, Mombelli, Matteo, and Manuel, Oriol
- Abstract
OBJECTIVES To describe the epidemiology and clinical presentation of central nervous system (CNS) infections in solid organ transplant (SOT) recipients in the current era of transplantation. METHODS Patients from the Swiss Transplant Cohort Study (STCS) transplanted between 2008 and 2018 were included with a median follow-up of 3.8 years. Epidemiological, microbiological, and clinical data were extracted from the STCS database and patients' medical records. We calculated incidence rates and 90-day survival of transplant recipients with CNS infection. RESULTS Among 4762 patients, 42 episodes of CNS infection in 41 (0.8%) SOT recipients were identified, with an overall incidence rate of 2.06 per 1000 patient-years. Incidence of CNS infections was similar across all types of transplantations. Time to CNS infection onset ranged from 0.6 to 97 months after transplant. There were 22/42 (52.4%) cases of viral infections, 11/42 (26.2%) of fungal infections, 5/42 (11.9%) of bacterial infections and 4/42 (9.5%) of probable viral/bacterial etiology. Clinical presentation was meningitis/encephalitis in 25 cases (59.5%) and brain-space occupying lesions in 17 cases (40.5%). Twenty-three cases (60.5%) were considered opportunistic infections. Diagnosis were achieved mainly by brain biopsy/necropsy (15/42, 36%) or by cerebrospinal fluid analysis (20/42, 48%). Up to 40% of cases (17/42) had concurrent extra-neurological disease localizations. Overall, 90-day mortality rate was 29.0% (73.0% for fungal, 14.0% for viral and 11.0% for bacterial and probable infections, p<0.0001). CONCLUSIONS CNS infections were rare in the STCS, with viral meningoencephalitis being the most common disease. Fungal infections were associated with a high mortality.
- Published
- 2022
48. Elimination of Herpes Simplex Virus-2 and Epstein-Barr Virus With Seraph 100 Microbind Affinity Blood Filter and Therapeutic Plasma Exchange: An Explorative Study in a Patient With Acute Liver Failure
- Author
-
Andermatt, Rea; https://orcid.org/0000-0001-8694-1271, Bloemberg, Guido V, Ganter, Christoph C, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Mueller, Antonia M S, Muellhaupt, Beat, Kielstein, Jan T, David, Sascha; https://orcid.org/0000-0002-8231-0461, Andermatt, Rea; https://orcid.org/0000-0001-8694-1271, Bloemberg, Guido V, Ganter, Christoph C, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Mueller, Antonia M S, Muellhaupt, Beat, Kielstein, Jan T, and David, Sascha; https://orcid.org/0000-0002-8231-0461
- Abstract
OBJECTIVES Herpes simplex virus (HSV)-2 is a rare cause of hepatitis that can lead to acute liver failure (ALF) and often death. The earlier the initiation of acyclovir treatment the better the survival. With regard to ALF, controlled randomized data support the use of therapeutic plasma exchange (TPE) both as bridge to recovery or transplantation-possibly by modulating the systemic inflammatory response and by replacing coagulation factors. Seraph 100 Microbind Affinity Blood Filter (Seraph; Ex Thera Medical, Martinez, CA), a novel extracorporeal adsorption device, removes living pathogens by binding to a heparin-coated surface was shown to efficiently clear HSV-2 particles in vitro. Here, we tested the combination of Seraph with TPE to reduce a massive HSV-2 viral load to reach a situation in that liver transplantation would be feasible. DESIGN Explorative study. SETTING Academic tertiary care transplant center. PATIENT Single patient with HSV-2-induced ALF. INTERVENTIONS TPE + Seraph 100 Microbind Affinity Blood Filter. MEASUREMENTS AND MAIN RESULTS We report Seraph clearance data of HSV-2 and of Epstein-Barr virus (EBV) in vivo as well as total viral elimination by TPE. Genome copies/mL of HSV-2 and EBV in EDTA plasma were measured by polymerase chain reaction every 60 minutes over 6 hours after starting Seraph both systemically and post adsorber. Also, HSV-2 and EBV were quantified before and after TPE and in the removed apheresis plasma. We found a total elimination of 1.81 × e$^{11}$ HSV-2 copies and 2.11 × e$^{6}$ EBV copies with a single TPE (exchange volume of 5L; 1.5× calculated plasma volume). Whole blood clearance of HSV-2 in the first 6 hours of treatment was 6.64 mL/min (4.98-12.92 mL/min). Despite much lower baseline viremia, clearance of EBV was higher 36.62 mL/min (22.67-53.48 mL/min). CONCLUSIONS TPE was able to remove circulating HSV-2 copies by 25% and EBV copies by 40% from the blood. On the other hand, clearance of HSV-2 by Seraph was clinical
- Published
- 2022
49. Safety Evaluation of a Medical Congress Held During the COVID-19 Pandemic-A Prospective Cohort
- Author
-
Sumer, Johannes, Flury, Domenica, Kahlert, Christian R; https://orcid.org/0000-0002-0784-3276, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Risch, Lorenz; https://orcid.org/0000-0003-2692-6699, Nigg, Susanne, Seneghini, Marco, Vernazza, Pietro; https://orcid.org/0000-0002-6849-6941, Schlegel, Matthias; https://orcid.org/0000-0003-2847-4956, Kohler, Philipp; https://orcid.org/0000-0003-0427-8934, Sumer, Johannes, Flury, Domenica, Kahlert, Christian R; https://orcid.org/0000-0002-0784-3276, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Risch, Lorenz; https://orcid.org/0000-0003-2692-6699, Nigg, Susanne, Seneghini, Marco, Vernazza, Pietro; https://orcid.org/0000-0002-6849-6941, Schlegel, Matthias; https://orcid.org/0000-0003-2847-4956, and Kohler, Philipp; https://orcid.org/0000-0003-0427-8934
- Abstract
Objectives: During the COVID-19 pandemic, few scientific congresses have been held on-site. We prospectively evaluated the safety concept of the congress of the Swiss Societies of Infectious Diseases and Hospital Hygiene. Methods: The congress was held in Geneva (Switzerland) while local COVID-19 incidence (with SARS-CoV-2 wild type circulating) was 65/100,000 population (September 2020). A rigorous safety concept was implemented. Congress attendees filled out a questionnaire to assess risk perception, exposures, symptoms and diagnoses of SARS-CoV-2 before, during and after the congress. Dried blood spots were taken on-site and 4 weeks later to detect SARS-CoV-2 seroconversions. Results: Of 365 congress attendees, 196 (54%) either answered the questionnaire (N = 150) or provided baseline and follow-up blood samples (N = 168). None of the participants reported a positive PCR in the 2 weeks after the congress. Five of 168 (3%) participants were seropositive at follow-up, all of which had already been positive at baseline. Conclusion: Findings indicate that congresses with a rigorous safety concept may take place, even in areas with moderately-high COVID-19 activity. Whether this holds true in vaccinated populations and with more transmissible viral variants circulating remains unclear.
- Published
- 2022
50. Porcine cytomegalovirus/porcine roseolovirus (PCMV/PRV): A threat for xenotransplantation?
- Author
-
Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Denner, Joachim; https://orcid.org/0000-0003-3244-6085, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, and Denner, Joachim; https://orcid.org/0000-0003-3244-6085
- Abstract
The potential for a donor-derived transmission of porcine cytomegalovirus/porcine roseolovirus (PCMV/PRV) to the recipient has been recognized since pigs were considered candidate donors for xenotransplantation. This review gives a short description of the viral properties and summarizes the current evidence of the effects of PCMV/PRV transmission in preclinical xenotransplantation. Despite evidence that PCMV/PRV does not infect human and non-human primate cells, activation in the transplanted organ and detrimental systemic complications have been described. As PCMV/PRV is a herpesvirus able to establish latency, the importance of adequate screening of donor pigs is emphasized, as no efficient treatment is available. Furthermore, easy and successful ways of elimination of PCMV/PRV from pig herds are indicated.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.